



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$46.80
Change (%)	▲ 0.51 (1.10%)
Volume	764,575
52 Week Low	\$27.94
Market Cap	\$1,936,697,724
Rolling EPS	1.62
PE Ratio	28.5429
Shares Outstanding	41,382,430

Data as of 12/15/17 4:06 p.m. ET



Recent Headlines & Events

12/12/17

Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government

11/30/17

Emergent BioSolutions to Host 2017 Analyst & Investor Day

11/20/17

Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/14/17	4
12/13/17	4
12/11/17	4
12/07/17	CT ORDER

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows

Vice President,
Investor Relations

Emergent BioSolutions Inc.

Phone: (240) 631 3280

Fax: (240) 413-1917

E-mail: burrowsr@ebsi.com